
简介:
- 作者: Geith Maal-Bared, Mandy Yee, Erika K. Harding, Martha Ghebreselassie, Michael Bergamini, Roxanne Choy, Ethan Kim, Stephanie Di Vito, Maryam Patel, Mohammadreza Amirzadeh, Taryn E. Grieder, James I. Nagy, Robert P. Bonin and Derek van der Kooya
- 杂志: BioRxiv
- Doi: https://www.doi.org/10.1101/2020.12.18.423554
- 出版日期: 2020 Dec 21
论文中使用的产品/服务
Quotation shows PackGene:These coordinates were used to deliver Cre-dependent AAVs carrying Cx36 (ssAAV9-Ef1a-DIO-Cx36) and EGFP (ssAAV9-Ef1a-EGFP-WPREs) at 5E+13 GC/mL in 0.1 mL. AAVs were obtained from Packgene.
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Adult male Wistar rats (250 – 400 grams) and C57BL/6 mice (20 – 35 grams) were acquired from Charles River (Montreal, Canada).
摘要
Drug dependence is characterized by a switch in motivation wherein a positively reinforcing substance becomes negatively reinforcing. Ventral tegmental area (VTA) GABA neurons form a point of divergence between two double dissociable pathways responsible for these respective motivational states. Here we show that this switch from drug-naïve to opiate-dependent and withdrawn (ODW) motivation is contingent upon the gap junction-forming protein, connexin-36 (Cx36), in VTA GABA neurons. Intra-VTA infusions of the Cx36 blocker, mefloquine, in ODW rats resulted in a reversion to a drug-naïve motivational state and a loss of opiate withdrawal aversions. Consistent with these data, conditional knockout mice lacking Cx36 in GABA neurons (GAD65-Cre;Cx36fl(CFP)/fl(CFP)) were perpetually drug-naïve and never experienced opiate withdrawal aversions. Further, viral-mediated rescue of Cx36 in VTA GABA neurons was sufficient to restore their susceptibility to ODW motivation. Our findings reveal a functional role for VTA gap junctions that has eluded prevailing circuit models of addiction.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
